Genomic selection (the analysis of the genome and selection of traits important to commercial. Experience with molecular biology (DNA and RNA extraction and…
From Genus PIC - Thu, 18 Nov 2021 07:29:05 GMT - View all DeForest, WI jobs

Work independently and in teams to develop, implement, and utilize phage naïve or immune libraries for antibody discovery and optimization.
From Indeed - Wed, 17 Nov 2021 23:52:23 GMT - View all Madison, WI jobs

£37,865 - £44,900: Wellcome Sanger Institute: The Opportunity:  We are seeking a talented bioinformatician or scientist, with strong informatics skills, who is interest in developing a dynamic,... Cambridge, Cambridgeshire

Significant experience in molecular biology, including PCR, qPCR, cloning, primers/gRNA design and CRISPR design, or strong bioinformatics skills, including…
From University of Wisconsin–Madison - Wed, 17 Nov 2021 18:57:34 GMT - View all Madison, WI jobs

Notice NOT-DE-21-020 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-EY-21-002 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) aims to support collaborative studies of a unique resource of patient-derived induced pluripotent stem cell (iPSC) lines generated by the NEI age-related macular degeneration (AMD) Integrative Biology Initiative. This resource also includes clinical, genomic, and imaging data from the patients from which these cells were derived, and a set of isogenic control cell lines in which the risk allele(s) have been corrected. These cell lines and clinical data are from patients with AMD carrying high prevalence risk alleles selected from the Age-Related Eye Disease Study 2 (AREDS2). The goal of this FOA is to determine if these iPSC-derived cell lines can be used to discover the underlying pathophysiology of AMD. Collaborative effort is highly encouraged with investigators bringing in the needed areas of expertise for successful projects.

Funding Opportunity RFA-RM-22-006 from the NIH Guide for Grants and Contracts. The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) with the vision of alleviating suffering from childhood cancer and structural birth defects by fostering collaborative research to uncover the etiology of these diseases and supporting data sharing within the pediatric research community. Kids First has established and continues to develop a Data Resource including a large collection of curated genomic and phenotypic data from childhood cancer and structural birth defects cohorts and a central portal where these data and analysis tools are accessible to the research community. This FOA is intended to engage experts in a variety of activities that will enhance the utility of childhood cancer and/or structural birth defects genomic datasets generated by the Kids First program and/or associated phenotypic datasets and resources. These activities should strengthen future analyses of Kids First datasets by the broader researcher community with the ultimate goal of improving diagnostic capabilities and therapies for children and their families affected by these conditions.

Notice NOT-CE-22-001 from the NIH Guide for Grants and Contracts

Notice NOT-HS-22-006 from the NIH Guide for Grants and Contracts

Competitive Salary: F. Hoffmann-La Roche AG: At Roche, we believe it’s urgent to deliver medical solutions right now – even as we develop innovations for the future. We are passionate about tran Switzerland (CH)

Notice NOT-HS-22-008 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-23-004 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) RFA supports secondary data analyses and/or data collection/enhancements to existing datasets to address the role of place (e.g., countries, U.S. Census regions, states, counties, neighborhoods, and locations across the urban-rural continuum) in health in order to uncover actionable knowledge to address disparities by geography and other factors such as race and ethnicity. Secondary data analyses appropriate to this FOA include those that: 1) clarify social, economic, behavioral, and ?institutional (e.g., federal to local government policies/programs, firm/industry practices, etc.) explanations for place-based health disparities (levels and trends) and/or 2) examine intersections between place and sociodemographic characteristics (e.g., gender, race, ethnicity, etc.) to better understand and address processes driving other ?health disparities. Analytic approaches that utilize quasi-experimental and other methods that yield causal estimates are preferred, though mixed methods projects that inform mechanistic insights and/or data enhancements are also appropriate. Multilevel analyses that enable the joint and synergistic examination of macro-, meso-, and individual-level factors are also encouraged.

Funding Opportunity PAR-22-055 from the NIH Guide for Grants and Contracts. This FOA invites applications from multidisciplinary teams to perform secondary data analysis, using existing datasets from two or more multi-site clinical research projects, to address scientific and clinical hypotheses relevant to neurological disorders and conditions within the NINDS mission. In this phased funding mechanism, applications are required to systematically and comprehensively perform cross-project data harmonization and curation, assessed using Go/No-go data-quality metrics, prior to funding of the second phase of data analyses. Consistent with the FAIR (findable, accessible, interoperable and reusable) data principles, this funding opportunity expects open-source cataloging of the processes and tools used for harmonization, curation, and analysis, as well as controlled access to the curated datasets.

Funding Opportunity RFA-HL-23-009 from the NIH Guide for Grants and Contracts. The Small Business Innovation Research (SBIR) Program is an important funding mechanism that the National Institutes of Health (NIH) uses to develop innovative solutions that address public health challenges. A major objective of the SBIR Program is to facilitate the commercialization of technologies developed by small business concerns (SBCs). Yet, the development of biomedical products is often impeded by a significant funding gap between the end of the SBIR Phase II award and the commercialization stage. This Funding Opportunity Announcement (FOA) invites SBIR grant applications from SBCs to support later later-stage research and development (referred to as Phase IIB) for promising projects that were previously funded by SBIR or STTR Phase II awards and will require eventual Federal regulatory approval/clearance. The goal of this FOA and the resulting Phase IIB awards is to assist applicants in pursuing the milestone(s) necessary to advance a product to regulatory approval and commercialization by promoting partnerships between SBIR Phase II awardees and third-party investors and/or strategic partners.

Funding Opportunity PAR-22-066 from the NIH Guide for Grants and Contracts. Reissue of PAR-19-027 This Funding Opportunity Announcement (FOA) solicits research projects focused on the dynamic and mechanistic links between the maturation of brain circuits and behaviors across development in rodents and non-human primates. The goal is to build a foundation for understanding how interactions within and among brain regions change over pre- and post-natal development, allowing for the emergence of cognitive, affective and social behaviors. To this end, projects supported will focus on neurodevelopmental trajectories in rodents or non-human primates and investigate questions using in vivo neural measures in awake, behaving animals. This FOA uses the R01 grant mechanism, whereas its companion funding opportunity seeks shorter, higher-risk R21 grant applications.

Funding Opportunity RFA-OH-22-001 from the NIH Guide for Grants and Contracts. The National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention (CDC), invites grant applications for funding Education and Research Centers (ERCs) that are focused on occupational safety and health training. NIOSH is mandated to provide an adequate supply of qualified personnel to carry out the purposes of the Occupational Safety and Health Act, and the ERCs are one of the principal means for meeting this mandate.

Funding Opportunity RFA-AT-22-003 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) intends to support the development of innovative quantitative imaging and other relevant biomarkers of myofascial tissues for pain management involving research participants using a two-phase grant funding mechanism. This effort is part of NIHs Helping to End Addiction Long-term (HEAL)SM Initiative to speed the development and implementation of scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative will bolster research across NIH to (1) improve treatment and prevention of opioid misuse and opioid use disorder and (2) enhance pain management. This funding opportunity announcement (FOA) seeks research applications to develop quantitative imaging biomarkers of myofascial tissues and assess their abilities to monitor responses and/or predict outcomes of a variety of pain management regimens. Candidates for the quantitative imaging biomarkers may include objective measures based on minimally invasive imaging technologies, electrophysiological recordings, integration of multiparametric imaging and electrophysiology approaches, or their integration with other markers (e.g., immune factors, genomic markers, physiological factors, etc.) through multiscale modeling or machine learning analysis. The first phase, funded by the R61, will provide funding for up to three years to develop quantitative measures that can differentiate myofascial tissue abnormalities in healthy versus latent, versus active myofascial pain stages using cross-sectional correlations with clinical signs/symptoms. In addition, the R61 phase should include team building and planning activities for the R33 phase. The second phase, funded under the R33, will provide up to two years of support to assess the abilities of the quantitative measures developed in the R61 phase to monitor responses and/or predict outcomes in response to specified therapies to relieve myofascial pain in longitudinal interventional studies.

Funding Opportunity RFA-DA-22-036 from the NIH Guide for Grants and Contracts. In April 2018, the National Institutes of Health (NIH) launched the Helping to End Addiction Long-termSMInitiative or HEAL InitiativeSM, an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. Through this initiative the National Institute on Drug Abuse, in partnership with other NIH Institutes, Centers, and Offices, requests applications for studies designed to develop and test multi-level interventions to prevent opioid misuse, opioid use disorder, and co-occurring conditionsby intervening on social determinants of health (SDOH).This initiative aims to build an evidence base for multi-level interventions that target malleable factors and conditions affecting the social context. Applications must seek to reduce health inequities in a U.S. population or population subgroup affected by the opioid crisis by studyingthe effects of a theory driven, multi-level intervention on the prevention of opioid misuse/opioid use disorder and co-occurring conditions. Such conditions could include mental health conditions and/or suicide, and may alsoinclude other substance use and substance use-related outcomes. The research project must examinethe mechanisms by which the interventions exert their effects, and conduct economic analyses to inform decisions about adoption of strategies. Investigators should study interventions that are sustainable and easily taken to scale if effective.

Funding Opportunity PAR-22-070 from the NIH Guide for Grants and Contracts. The National Eye Institute (NEI) Audacious Goal Initiative (AGI) is an effort to push the boundaries of vision science and restore vision through regeneration of cells in the retina. AGI research specifically targets photoreceptors (PRCs) and retinal ganglion cells (RGCs) in the eye. Photoreceptors often called rods and cones are cells in the retina that, when stimulated by light, generate signals the brain perceives as images. The retinal ganglion cells carry these signals from the photoreceptors to the brain. Although there has been some success in regenerating retinal neurons and connections in fish, mice, and other systems, the ultimate goal of the AGI is to restore vision in humans.

Funding Opportunity RFA-HL-23-008 from the NIH Guide for Grants and Contracts. The Small Business Innovation Research (SBIR) Program is an important National Institutes of Health (NIH) funding mechanism used to develop innovative solutions that address public health challenges. A major objective of the SBIR Program is to facilitate the commercialization of technologies developed by small business concerns (SBCs). Yet, the development of biomedical products is often impeded by a significant funding gap between the end of the SBIR Phase II award and the commercialization stage. This gap is increased by the barriers associated with technologies under development for small commercial markets, such as those focused on rare diseases or young pediatric populations. This Funding Opportunity Announcement (FOA) invites small businesses to submit SBIR grant applications to support later stage research and development (referred to as Phase IIB) for promising projects that were previously funded by SBIR or STTR (Small Business Technology Transfer) Phase II awards that address rare diseases or young pediatric populations (aged 0-12 years and defined in Section IV, part 7), and will require eventual Federal regulatory approval/clearance. The goal of this FOA and the resulting Phase IIB awards is to assist applicants in pursuing the next appropriate milestone(s) necessary to advance a product to regulatory approval and commercialization by promoting partnerships between small business awardees and third-party investors and/or strategic partners, including patient advocacy organizations.